Girls with attention deficit hyperactivity disorder (ADHD) who were prescribed osmotic-release oral system methylphenidate hydrochloride (OROS-MPH) and pediatric patients who had concomitant atomoxetine or hypnotic therapy were at increased risk for poor OROS-MPH adherence. These findings from a retrospective survey were published in Scientific Reports.